

# The prevalence of HIV infection among blood donors: a systematic review and meta-analysis

Leila Kasraian<sup>1</sup>, Sahar Hosseini<sup>2</sup>, Alireza Ebrahimi<sup>3</sup>, Rohan Bhimani<sup>3</sup>, Soheil Ashkani-Esfahani<sup>3</sup>

<sup>1</sup>Blood Transfusion Research Centre, High Institute for Research and Education in Transfusion, Shiraz University of Medical Sciences, Shiraz, Iran

<sup>2</sup>Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran

<sup>3</sup>Department of Orthopedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA

## Abstract

Blood recipients, particularly frequent receivers, are at high-risk of receiving human immunodeficiency virus (HIV), and no current serologic tests eliminate this transmission risk. The current paper aimed to provide an updated comprehensive report on the prevalence of HIV infection among blood donors in different parts of the world.

HIV infection prevalence in blood donors was determined based on electronically published data through a systematic review of literature in international databases until February 2020. Studies published in Farsi and English reporting the prevalence of HIV were included. Meta-analysis was performed, and final results were classified according to World Health Organization (WHO) divisions of the world.

Out of 1,859 articles, 241 met the inclusion criteria. The prevalence of HIV was higher in first-time donors, males, and replacement therapy receivers. The pooled prevalence was 502.74 in 100,000. AFRO with 2,384.99 and Europe with 19.04 in 100,000 had the highest and the lowest rates, respectively. Gabon represented the highest rate of 20,623, while the USA showed the lowest rate, i.e., 4.33, among the countries.

Updated reports on the prevalence of HIV among blood donors help policy-makers and care providers realize the possible need for improving the screening, diagnostics, and treatment protocols. Although the prevalence has decreased in many parts of the world, improving the current protocols is still necessary to minimize the risks in transfusion systems.

HIV AIDS Rev 2024; 23, 1: 1-14

DOI: <https://doi.org/10.5114/hivar.2024.135574>

**Key words:** HIV, AIDS, epidemiology, blood donation.

## Introduction

The recognition of transfusion-transmissible infections (TTIs) has indicated a new horizon in blood transfusion practice all around the world, with an emphasis on two

primary objectives, such as safety and protection of human life [1].

Blood safety has remained an issue of major concern, especially in regions where transfusion services, policies, infrastructure, trained staff, and financial resources are insuf-

**Address for correspondence:** Alireza Ebrahimi,  
Department of Orthopaedic Surgery, Massachusetts General  
Hospital, Harvard Medical School, Boston, Massachusetts, USA,  
e-mail: Alireza.ibrahim92@gmail.com

**Article history:**  
Received: 17.01.2022  
Received in revised form: 13.06.2022  
Accepted: 01.07.2022  
Available online: 21.02.2024



ficient. Blood recipients, particularly those who frequently receive transfusions, are at high-risk for acquiring TTIs, including human immunodeficiency virus (HIV) infection, and unfortunately, serologic tests do not eliminate the transmission risk of HIV [2, 3].

Accurate, current, and timely public health surveillance information on HIV prevalence is necessary to guide decisions for planning disease prevention, program evaluation, and allocation of resources at the local and national levels [4]. According to the literature, about 40 million patients are infected with HIV globally, and over 30 million have died due to this infection and its complications [5]. The most significant portion of this mortality rate is assigned to developing countries [5]. Ensuring blood safety in transfusions and implementing screening of HIV using nucleic acid testing (NAT), played a significant role in reducing the transmission rate, especially in pioneer countries, such as the United States, after 1999 [6]. Investigations both before and shortly after using NAT showed measurable advantages in the prevention of potential transfusion transmissions attributed to the reduction in window periods [5, 7-11].

TTIs have been drastically reduced in countries where routine serologic screening of donors was conducted [12, 13]. In Iran, screening of blood donations for HIV became mandatory in 1989. Another survey from Iran evaluating the general population in 1999 reported a prevalence of 0.86 in 10,000, while a newer official report of 2007 showed an increased rate of 2.3 in 10,000 identified cases of infection [14, 15]. According to the latest information, the proportion of blood donation in the transmission of the disease in Iran was 0.9%; however, more recent reports showed that although the prevalence is increasing at a slow pace, no case of HIV infection was diagnosed due to blood products [16].

Evaluation of the published literature on the prevalence of HIV among blood donors provides valuable data on the occurrence of this infection in population and, consequently, the safety of donated products in various regions. In this paper, we presented a brief review and a meta-analysis of the prevalence of HIV infection among blood donors all over the world, with the attempt to highlight the global burden of this TTI.

## Material and methods

The prevalence of HIV infection in blood donors based on any published data from Iran and other countries all over the world was investigated through a comprehensive

systematic review of the literature, followed by integrating of the data and analysis of the outcomes.

## Search strategy and method


An electronic systematic search algorithm in international databases, such as PubMed, ISI, Scopus, and ProQuest were adopted for articles published till February 2020, using the following keywords: (“blood donors” OR “blood donation” OR “donor” OR “donation” OR “blood” OR “blood safety” OR “bloodborne” OR “residual risk” OR “transfusion-transmitted infections”) AND (“prevalence” OR “epidemiology”) in combination with (“HIV” OR “human immunodeficiency virus” OR “AIDS” OR “HIV/AIDS”). Google Scholar and Iranian databases, Scientific Information Database (SID, www.sid.ir), and Magiran (<http://www.magiran.com>) were searched for published articles in Farsi/Persian language. References of the reviews, systematic reviews, meta-analyses, and relevant retrieved articles were explored to increase the sensitivity. All the literature was imported into EndNote® software version X9, and screened for eligibility criteria. Inclusion criteria for consideration of the studies were based on preferred reporting items for systematic reviews and meta-analyses (PRISMA) checklist (Table 1). At first, titles and/or abstracts of studies were reviewed by a single reviewer (SAE). Only studies on blood donors published in English that measured the prevalence of HIV/AIDS were included in the systematic review. Exclusion criteria were insufficient statistical information about the prevalence and number of positive cases, and specific blood donors’ population (i.e., studies that recruited only HBS-positive blood donors). Two reviewers (SH and AE) screened the abstracts and independently applied inclusion criteria to full texts. Duplicate and overlapping studies were also excluded.

## Data collection and data items

One reviewer (LK) extracted the data and double-checked for the following items: authors’ names, publication year, study period, location, sample size, prevalence of HIV/AIDS, and blood donation status (first time, lapsed, and regular blood donor). If ambiguity was present in a study information extraction, it was resolved by a statistician (MSM).

**Table 1.** Study inclusion criteria

Study population	Any individual who had donated blood
Geographical setting	No restrictions
Blood donation status	Individuals might have donated blood for first time, second time, or regularly
HIV screening	Antigen/antibody tests, nucleic acid testing
Study design	Any study design with data on the prevalence of HIV/AIDS in blood donors



**Figure 1.** Flow diagram of systematic review and searches for HIV infection prevalence among blood donors in countries all over the world

**Table 2.** Demographic data of global prevalence of HIV infection among blood donors

Criterion/Condition	No. of studies	No. of blood donors	No. of infected donors	Prevalence of HIV in 100,000	95% confidence interval
Donation status					
First time	12	5,918,554	13,367	2,702	913-5,391
Regular	3	36,370,841	3,165	1,214	162-3,170
Gender					
Male	15	850,599	1,782	2,940	2,356-3,586
Female	13	482,402	1,153	2,412	1,579-3,389
Reason of donation					
Replacement	11	82,513	1,773	2,325	1,313-3,616
Voluntarily	8	43,369	176	1,378	355-2,990

### Statistical analysis

Meta-analysis was conducted using Metaprop command in STATA version 14.0 (Stata Corp., College Station, TX, USA) [17]. The extracted data included first author, year of the study, location, sample population, sampling method and sample size, HIV/AIDS detection method, age, male to female ratio, and HIV point prevalence among the subjects. Cochrane Q-test was used with a significance level of less than 0.1 for statistical heterogeneity of the results. To assess the level of heterogeneity, a range of 0% (no heterogeneity) to 100% (significant heterogeneity) was considered during

the analysis; values of 25%, 50%, and 75% were labeled as representing low, medium, and high heterogeneity, respectively [18]. Whenever heterogeneity of a study was significant ( $p < 0.1$ ), a random effect meta-analysis was used; otherwise, a fixed effect meta-analysis was applied to combine the prevalence. Countries were grouped according to the World Health Organization (WHO) list of countries of each regional office, namely, African Regional Office (AFRO), Region of the Americas (AMRO), South-East Asia Regional Office (SEARO), European Region (EURO), Eastern Mediterranean Regional Office (EMRO), and Western Pacific Regional Office (WPRO) [19].

**Table 3.** Part 1: Prevalence of HIV in different regions of the world (according to WHO regional divisions), and in different countries based on published literature

Study	No. of studies	Prevalence	95% confidence interval		% weight	<i>I</i> <sup>2</sup>	Reference
WPRO						99.8%	
China	5	78.746	76.792	80.701	2.96		[30-34]
Philippines	1	6.324	0.127	12.522	2.95		[35]
Pooled prevalence	6	42.597	-28.375	113.570	5.91		
SEARO						99.8%	
Bangladesh	2	4,203.224	3,641.436	4,765.012	0.10		[36, 37]
Bengal	2	212.991	194.489	231.493	2.87		[38, 39]
India	45	340.764	336.007	345.521	2.95		[40-84]
Indonesia	1	914.849	419.820	1,409.877	0.13		[83]
Nepal	1	20.027	5.193	34.861	2.90		[85]
Sri Lanka	2	32.719	19.049	46.389	2.91		[86, 87]
Thailand	3	476.814	423.517	530.110	2.35		[88-90]
Pooled prevalence	56	489.078	326.403	651.752	14.22		
AMRO						99.7%	
Brazil	8	157.927	149.593	166.262	2.94		[91-98]
Canada	1	30.979	-29.729	91.687	2.22		[99]
Ecuador	1	2,186.705	2,010.091	2,363.319	0.77		[100]
Mexico	4	99.455	83.600	115.310	2.89		[101-104]
Haiti	1	13.755	6.794	20.715	2.95		[105]
USA	1	4.333	3.853	4.814	2.96		[106, 107]
Venezuela	1	243.729	201.883	285.575	2.55		[107]
Pooled prevalence	17	246.710	180.959	312.460	17.29		
AFRO						99.9%	
Angola	1	1,744.979	1,656.588	1,833.370	1.73		[108]
Burkina Faso	2	390.505	328.546	452.463	2.19		[109, 110]
Cameron	6	2,305.511	2,074.563	2,536.459	0.51		[32, 111-115]
Congo	4	175.247	169.678	180.815	2.95		[116-119]
Côte d'Ivoire	1	3,832.174	3,774.276	3,890.072	2.27		[120]
Djibouti	1	1,943.149	1,658.064	2,228.234	0.35		[121]
Eritrea	2	313.116	195.195	431.037	1.31		[122, 123]
Ethiopia	17	895.087	853.242	936.931	2.55		[124-140]
Gabon Province	3	2.1e+04	1.8e+04	2.3e+04	0.01		[141-143]
Ghana	2	3,678.723	3,596.256	3,761.189	1.83		[144, 145]
Guiana	1	7,831.120	6,859.492	8,802.749	0.03		[146]
Kenya	5	3,797.200	3,251.594	4,342.806	0.11		[147-151]
Malawi	2	2,530.578	2,367.355	2,693.801	0.87		[152, 153]
Mali	2	2,481.995	2,315.651	2,648.340	0.84		[154, 155]
Namibia	1	302.896	234.449	371.342	2.08		[156]
Nigeria	15	2,954.379	2,874.456	3,034.303	1.87		[157-171]
Sierra Leone	1	2,804.625	2,555.444	3,053.806	0.45		[172]
South Africa	2	468.076	455.599	480.553	2.92		[173, 174]
Sudan	1	1,364.522	360.609	2,368.436	0.03		[175]
Tanzania	4	2,874.800	2,653.214	3,096.385	0.54		[176-179]
Zimbabwe	1	658.163	624.234	692.092	2.68		[180]
Pooled prevalence	74	2,348.989	2,016.136	2,681.843	28.12		

**Table 3.** Part 1: Cont.

Study	No. of studies	Prevalence	95% confidence interval		% weight	$I^2$	Reference
EUROPE						98.9%	
France	1	19.105	15.795	22.414	2.96		[181]
Italy	1	6.077	5.641	6.514	2.96		[182]
Saxony	1	5.419	2.916	7.922	2.96		[183]
Serbia	1	12.952	11.221	14.683	2.96		[184]
Spain	1	65.780	59.461	72.100	2.95		[185]
Turkey	12	9.730	7.347	12.114	2.96		[186-197]
Pooled prevalence	17	19.041	11.720	26.363	17.74		
EMRO							
Egypt	2	11.094	5.283	16.904	2.95		[198, 199]
Iraq	2	49.605	29.338	69.873	2.85		[200, 201]
Pakistan	12	42.547	35.976	49.118	2.95		[202-213]
Palestine	1	7.636	5.327	9.946	2.96		[214]
Saudi Arabia	3	69.725	39.178	100.273	2.73		[215-217]
Yemen	4	419.874	363.205	476.543	2.29		[218-221]
Pooled prevalence	24	72.523	46.979	98.067	16.73		
Overall						99.9%	
Pooled prevalence	194	502.744	484.696	520.793	100.00		

**Table 3.** Part 2: Prevalence of HIV in different cities of Iran based on published literature

Study	No. of studies	Pooled prevalence	95% confidence interval		% weight	$I^2$	References
Bushehr	3	4.600	2.272	6.927	6.91	97.6%	[193, 222]
Chabahar	1	1,294.139	992.942	1,595.337	0.00		[223]
Fars	5	7.479	6.453	8.505	7.98		[224-228]
Qom	1	5.603	-5.378	16.583	1.51		[229]
Golestan	3	1.197	-0.462	2.855	7.53		[230-232]
Gilan	1	8.029	0.161	15.897	2.51		[233]
Hamedan	1	5.463	-5.244	16.169	1.58		[234]
Ilam	3	0.785	0.341	1.230	8.24		[235-237]
Isfahan	4	0.641	0.013	1.269	8.18		[238-241]
Kerman	2	1.816	0.829	2.803	8.01		[242, 243]
Kermanshah	1	13.420	-1.765	28.606	0.87		[244]
Mazandaran	2	1.097	-0.423	2.618	7.64		[245, 246]
Semnan	1	9.467	0.190	18.744	1.98		[247]
Tehran	6	7.093	6.687	7.500	8.24		[248-253]
Yazd	1	1.570	0.031	3.109	7.63		[254]
Kurdistan	1	6.074	2.637	9.510	5.77		[255]
Kohgiluyeh and Boyer-Ahmad	2	4.224	2.154	6.293	7.16		[256, 257]
Iran	2	3.966	3.754	4.177	8.28		[258, 259]
Ardebil	1	Excluded					[260]
Khorasan	2	Excluded					[261, 262]
Zanjan	1	Excluded				[263]	
Qazvin	1	Excluded				[264]	
Arak	1	Excluded				[265]	
Yasuj	1	Excluded				[266]	
Overall	47	3.745	2.250	5.240	100.00		

## Results

In the electronic search of PubMed, Web of Science, Scopus, ProQuest, and local databases for HIV infections in different countries, 487, 518, 569, 223, and 62 papers were identified. After exclusion of duplicated articles ( $n = 671$ ), reviews ( $n = 8$ ), irrelevant articles ( $n = 765$ ), and non-English and non-Persian papers ( $n = 21$ ), by reviewing the titles and abstracts, articles with insufficient information ( $n = 76$ ), and those with unrelated population ( $n = 59$ ) were all excluded. In total, 259 out of 1,859 articles met the inclusion criteria. Of these, 18 papers reported the prevalence of HIV based on testing blood donors; thus, the exclusion of these papers reduced the final inclusion list to 241 papers (Figure 1).

As shown in Table 2, the prevalence rates of HIV were higher in first-time blood donors, males, and those receiving replacement therapies, globally. However, age and educational classifications were not recorded due to lack of data in the papers. The total number of HIV cases in the world excluding Iran's data was 78,324 (ranging from 0 to 19,646) among a total sample size of 44,785,054, ranging from 206 to 12,258,587. The pooled prevalence of HIV was 502.74 in 100,000 population (95% CI: 484.69-520.79%); test for heterogeneity:  $Q = 37343.16$ ,  $df = 99.9\%$ ,  $p < 0.001$ ,  $I^2 = 99.9\%$ ,  $Tau^2 = 5200.95$ ). As presented in part 1 of Table 3, AFRO division showed the highest prevalence rate (3481.37 in 100,000), while Europe (19.04 in 100,000) presented the lowest prevalence rate. Among the countries, Gabon depicted the highest rate (20,623 in 100,000), while the USA showed the lowest prevalence (4.33 in 100,000). In part 2 of Table 3, in Iran, the pooled prevalence was 3.74 in 100,000 (95% CI: 2.25-5.24%; test for heterogeneity:  $Q = 646.74$ ,  $df = 14\%$ ,  $p < 0.001$ ,  $I^2 = 97.6\%$ ,  $Tau^2 = 54.95$ ) with the highest rate in Chabahar (1,294.14 in 100,000) and the lowest in Isfahan (0.64 in 100,000) cities.

## Discussion

The WHO suggests screening of all donated blood for infections prior to use. Examining the blood products for HIV, hepatitis B virus, hepatitis C virus, and syphilis should be mandatory and conducted regardless of the quality system requirements. Among reporting countries, more than 13 were unable to perform the screening tests for all donated blood units for at least one of the afore-mentioned infections [20]. According to the WHO's 2017 report, the prevalence rates of HIV infection in blood donations in high-income, upper-middle-income, lower-middle-income, and low-income countries are 0.003%, 0.08%, 0.20%, and 1.08%, respectively [20]. This report indicates that the economic situation and subsequent facilities of a country have a direct influence on the risk of infection in blood products.

The current study presented the prevalence of HIV infection considering the published data from countries all over the world, and compared the outcomes with the prevalence of HIV in Iranian population. As demonstrated,

the EURO division had the lowest prevalence, which could be because of a better economic situation in European countries compared with other regions. Saxony territory had the most HIV-free blood units, and Spain had the highest HIV prevalence. Correspondingly, the poorest region, which is AFRO division, had the highest prevalence of all. Gabon appeared to be the most prevalent country for HIV-infected blood donations, and Congo had the lowest rate. In SEARO, Nepal showed the lowest prevalence, while Bangladesh, the poorest country in the region, demonstrated the highest rate. In AMRO, Ecuador and the USA had the highest and the lowest prevalence of HIV in blood units, respectively. However, the overall prevalence was low in WPRO division; Philippines and China had the lowest and the highest rates according to their published information, respectively. In EMRO, the lowest prevalence belonged to Iran, particularly in Isfahan Province, and the highest was observed in Yemen, which has been in a dire economic situation and even war during these years. These findings showed that the socio-economic status of a country, and the subsequent effects of economic situation on available facilities could have a direct impact on the prevalence of HIV as well as the provision of sufficient screening equipment. In order to achieve the eradication of the virus from blood units, several activities should be adopted, including improving health-care policies, screening systems, and diagnostic methods, educating the staff and the population, providing sufficient treatment, and managing the sources of infection [21-24]. Behavioral changes, such as reducing multiple and concurrent partners apart from using protection have been noticed as the main tools to prevent AIDS epidemics in regions, such as African countries [25-29]. Preventive care should be implemented at all levels to reduce the incidence of HIV infection and its complications. The limitations of this study were an inadequate number of studies from various countries and the absence of records in many countries, which did not allow the delivery of a better evaluation and more comprehensive outcomes.

## Conclusions

Our report demonstrated that the overall prevalence of HIV among blood donations has noticeably declined worldwide. However, compared with industrialized countries, the infection was high in developing regions, especially in AFRO division. In order to reduce the infection and increase blood donation safety, policy-makers must design comprehensive strategies according to updated academic literature. Developed countries should share their knowledge, experience, and facility with lower socio-economic countries to decrease the HIV infection among blood donors and the whole population, considering the fact that having the disease not controlled in one region may affect health status of the entire world.

## Acknowledgments

The authors would like to thank Medipress Co. and SIMR Co. for helping in preparing and editing the draft of the paper as well as in finalization of the article.

## Conflict of interest

The authors declare no conflict of interest.

## References

- Seghatchian M. New horizons in blood transfusion medicine: present status and future trends. *Transfus Sci* 1996; 17: 331-334.
- Ahn J, Cohen SM. Transmission of human immunodeficiency virus and hepatitis C virus through liver transplantation. *Liver Transpl* 2008; 14: 1603-1608.
- Kucirka LM, Sarathy H, Govindan P, et al. Risk of window period HIV infection in high infectious risk donors: systematic review and meta-analysis. *Am J Transplant* 2011; 11: 1176-1187.
- CDC. Advancing HIV prevention: new strategies for a changing epidemic – United States. Centers for Disease Control and Prevention; 2003. Available from: <https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5215a1.html>.
- WHO. Blood safety and availability. World Health Organization; 2017. Available from: <http://www.who.int/mediacentre/factsheets/fs279/en/>.
- Stramer SL. US NAT yield: where are we after 2 years? *Transfus Med* 2002; 12: 243-253.
- Dodd R, Stramer S, Aberle-Grasse J, Notari E. Risk of hepatitis and retroviral infections among blood donors and introduction of nucleic acid testing (NAT). *Develop Biol* 2000; 102: 19-27.
- Dodd R, Notari ET, Stramer S. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. *Transfusion* 2002; 42: 975-979.
- Stramer SL, Glynn SA, Kleinman SH, et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. *N Engl J Med* 2004; 351: 760-768.
- Busch MP, Glynn SA, Stramer SL, et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. *Transfusion* 2005; 45: 254-264.
- Zou S, Dorsey KA, Notari EP, et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. *Transfusion* 2010; 50: 1495-1504.
- Chiavetta JA, Escobar M, Newman AM, et al. Incidence and estimated rates of residual risk for HIV, hepatitis C, hepatitis B and human T-cell lymphotropic viruses in blood donors in Canada, 1990-2000. *Can Med Assoc J* 2003; 169: 767-773.
- Amini Kafi-abad S, Rezvan H, Abolghasemi H, Talebian A. Prevalence and trends of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus among blood donors in Iran, 2004 through 2007. *Transfusion* 2009; 49: 2214-2220.
- Massarrat MS, Tahaghoghi-Mehrzi S. Iranian national health survey: a brief report. *Arch Iranian Med* 2002; 5: 73-79.
- Haghdoost AA, Mostafavi E, Mirzazadeh A, et al. Modelling of HIV/AIDS in Iran up to 2014. *J AIDS HIV Res* 2011; 3: 231-239.
- On Monitoring of the United Nations General Assembly Special Session on HIV and AIDS National Advisory Council for Healthcare Research and Quality: Ministry of Health and Medical Education; 2015. Available from: [https://www.unaids.org/sites/default/files/country/documents/IRN\\_narrative\\_report\\_2015.pdf](https://www.unaids.org/sites/default/files/country/documents/IRN_narrative_report_2015.pdf).
- Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. *Arch Public Health* 2014; 72: 39. DOI: 10.1186/2049-3258-72-39.
- Ades A, Lu G, Higgins J. The interpretation of random-effects meta-analysis in decision models. *Med Decis Making* 2005; 25: 646-654.
- WHO. Definition of regional groupings. World Health Organization; 2017. Available from: [http://www.who.int/healthinfo/global\\_burden\\_disease/definition\\_regions/en/](http://www.who.int/healthinfo/global_burden_disease/definition_regions/en/).
- WHO. Blood safety and availability. WHO Fact Sheet. World Health Organization; 2017.
- Shisana O, Rehle T, Simbayi L, et al. South African HIV prevalence incidence behaviour and communication survey 2008: a turning tide among teenagers? Cape Town: HSRC Press; 2009.
- Gregson S, Garnett GP, Nyamukapa CA, et al. HIV decline associated with behavior change in eastern Zimbabwe. *Science* 2006; 311: 664-666.
- Green EC, Witte K. Can fear arousal in public health campaigns contribute to the decline of HIV prevalence? *J Health Commun* 2006; 11: 245-259.
- Porco TC, Martin JN, Page-Shafer KA, et al. Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. *AIDS* 2004; 18: 81-88.
- Stoneburner RL, Low-Beer D. Population-level HIV declines and behavioral risk avoidance in Uganda. *Science* 2004; 304: 714-718.
- Halperin DT, Epstein H. Concurrent sexual partnerships help to explain Africa's high HIV prevalence: implications for prevention. *Lancet* 2004; 364: 4-6.
- Sandøy IF, Michelo C, Siziya S, Fylkesnes K. Associations between sexual behaviour change in young people and decline in HIV prevalence in Zambia. *BMC Public Health* 2007; 7: 60. doi: 10.1186/1471-2458-7-60.
- Fylkesnes K, Musonda RM, Sichone M, Ndhlovu Z, Tembo F, Monze M. Declining HIV prevalence and risk behaviours in Zambia: evidence from surveillance and population-based surveys. *AIDS* 2001; 15: 907-916.
- Ghys PD, Diallo MO, Ettiègne-Traoré V, et al. Increase in condom use and decline in HIV and sexually transmitted diseases among female sex workers in Abidjan, Côte d'Ivoire, 1991-1998. *AIDS* 2002; 16: 251-258.
- Wang J, Liu J, Yao F, et al. Prevalence, incidence, and residual risks for transfusion-transmitted human immunodeficiency virus types 1 and 2 infection among Chinese blood donors. *Transfusion* 2013; 53: 1240-1249.
- Abdulkader M, Kengne M, Tsata DCW, Ndomgue T, Nwobegahay JM. Prevalence and risk factors of HTLV-1/2 and other blood borne infectious diseases among blood donors in Yaounde Central Hospital, Cameroon. *J Med Virol* 2018; 30: 125. DOI: 10.11604/pamj.2018.30.125.14802
- Chang L, Zhao J, Guo F, et al. Demographic characteristics of transfusion-transmitted infections among blood donors in China. *BMC Infect Dis* 2019; 19: 514. DOI: 10.1186/s12879-019-4044-x.
- Chen JT, Wang CE, Pan XH, Yu L, Jiang J, Sun MJ. HIV infection status and characteristics of non-remunerated blood donors in Hangzhou, 2008-2017. *Zhonghua Liu Xing Bing Xue Za Zhi* 2019; 40: 322-326 [Article in Chinese].
- Meng ZH, Yang J, Zhou HP, Yan LX. Retrospective study on HIV infection among blood donors in Zhejiang Province over 11-year period (1993-2004). *Zhongguo Shi Yan Xue Ye Xue Za Zhi* 2006; 14: 1231-1233 [Article in Chinese].
- Azerefeñ E, Worku M, Hailemariam M. Transfusion-transmissible infections among blood donors at Hawassa Regional Blood Bank Center, South Ethiopia. *Int J Res Stud Microbiol Biotechnol* 2018; 4: 10-16.
- Yanase Y, Ohida T, Kaneita Y, et al. The prevalence of HIV, HBV and HCV among Filipino blood donors and overseas work visa applicants. *Bull World Health Organ* 2007; 85: 131-137.
- Rudra S, Chakrabarty P, Hossain MA, Akhter H, Bhuiyan MR. Seroprevalence of hepatitis B, hepatitis C, HIV infections in blood donors of Khulna, Bangladesh. *Mymensingh Med J* 2010; 19: 515-519.

38. Ara F, Alam AM, Rahman M, et al. Prevalence of transfusion transmitted infection among blood donors at medical university in Bangladesh. *Journal of Shaheed Suhrawardy Medical College* 2014; 6: 11-13.
39. Choudhury B, Chattopadhyay D. Prevalence of human immunodeficiency virus among voluntary blood donors in a semi-urban setting in West Bengal. *J Med Sci Clin Res* 2019; 07: 264-266.
40. Bhattacharya P, Chandra PK, Datta S, et al. Significant increase in HBV, HCV, HIV and syphilis infections among blood donors in West Bengal, Eastern India 2004-2005: exploratory screening reveals high frequency of occult HBV infection. *World J Gastroenterol* 2007; 13: 3730-3733.
41. Makroo RN, Chowdhry M, Bhatia A, Arora B, Rosamma NL. Prevalence of HIV among blood donors in a tertiary care centre of north India. *Indian J Med Res* 2011; 134: 950-953.
42. Deshpande RH, Bhosale S, Gadgil PA, Sonawane M. Blood donor's status of HIV, HBV, HCV and syphilis in this region of Marathwada, India. *J Krishna Inst Med Sci University* 2012; 1: 111-116.
43. Dhruva Gauravi A, Agravat Amit H, Pujara Krupal M. Seroprevalence of HIV, HBV, HCV and syphilis in blood donors in saurashtra region of Gujarat: declining trends over a period of 31/2 years. *Online Journal of Health and Allied Sciences* 2012; 11: 5.
44. Ekadashi R, Langer S. Seroprevalence of human immunodeficiency virus and syphilis in blood donors of Delhi. *Indian J Med Microbiol* 2009; 27: 167-168.
45. Gupta N, Kaur A. Study of prevalence & correlation between HIV and syphilis among blood donors in a teaching hospital, Ludhiana, India. *Indian J Med Sci* 2002; 56: 161-164.
46. Kannangai R, Nair SC, Sridharan G, Prasannakumar S, Daniel D. Frequency of HIV type 2 infections among blood donor population from India: a 10-year experience. *Indian J Med Microbiol* 2010; 28: 111-113.
47. Kumar R, Gupta S, Kaur A, Gupta M. Individual donor-nucleic acid testing for human immunodeficiency virus-1, hepatitis C virus and hepatitis B virus and its role in blood safety. *Asian J Transfus Sci* 2015; 9: 199-202.
48. Kumar RR, Jayshree RS, Sridhar H. Prevalence of HIV infection in voluntary blood donors and cancer patients. *Indian J Pathol Microbiol* 1996; 39: 187-189.
49. Sonth SB, Solabannavar SS, Baragundi MC, Patil CS. The prevalence of HIV-2 seropositivity in blood donors. *J Clin Diagn Res* 2010; 4: 3091-3094.
50. Singh YN, Malaviya AN, Tripathy SP, et al. Human immunodeficiency virus infection in the blood donors of Delhi, India. *J Acquir Immune Defic Syndr* (1988) 1990; 3: 152-154.
51. Singh B, Verma M, Kotru M, Verma K, Batra M. Prevalence of HIV and VDRL seropositivity in blood donors of Delhi. *Indian J Med Res* 2005; 122: 234-236.
52. Shukla RS, Bhuyan KK. Can data on HIV sero-reactivity among blood donors provide an insight into HIV prevalence in the general population? *Indian J Public Health* 2007; 51: 14-21.
53. Pahuja S, Sharma M, Baitha B, Jain M. Prevalence and trends of markers of hepatitis C virus, hepatitis B virus and human immunodeficiency virus in Delhi blood donors: a hospital based study. *Jpn J Infect Dis* 2007; 60: 389-391.
54. Arora D, Arora B, Khetarpal A, Khetarpal S, Jindal U. Seroprevalence of HIV, HBV, HCV and syphilis in blood donors in Southern Haryana. *Ann Biol* 2010; 26: 1-4.
55. Agarwal N, Dubey U, Agarwal A, Jaiswal R. Hepatitis B or hepatitis C: the bigger threat in multiple infected HIV positive blood donors. *J Clin Diagn Res* 2011; 5: 766-768.
56. Ray K, Gupta SM, Bala M. Prevalence of HIV antibodies in replacement blood donors in Delhi, India. *J Acquir Immune Defic Syndr* 2001; 26: 393-394.
57. Chatterjee R, Tarwater P, Neogi D, et al. Estimation of HIV seroprevalence in blood bank camps in Kolkata, India. *Transfus Med* 2004; 14: 77-78.
58. Singhvi A, Pulimood RB, John TJ, et al. The prevalence of markers for hepatitis B and human immunodeficiency viruses, malarial parasites and microfilaria in blood donors in a large hospital in South India. *J Trop Med Hyg* 1990; 93: 178-182.
59. Anusha P, Jain K, Brahmane R, Chandi DH. Serorevalence of HIV and HBsAg amongst blood donors in a tertiary care hospital. *Chhattisgarh International Journal of Medical and Biomedical Studies* 2019; 3. DOI: 10.32553/ijmbs.v3i8.495.
60. Arora I, Singh S, Singh S. Seroprevalence and trends of transfusion transmitted infections in blood donors of rural tertiary care hospital blood bank: a 3 year retrospective study in Chamba (HP). *Int J Commun Med Public Health* 2018; 5: 2453-2457.
61. Barla M, Pailoor K, Keshava M. Transfusion transmitted infections among voluntary blood donors from rural areas in coastal Karnataka, India. *Hematol Transfus Int J* 2018; 6: 119-121.
62. Chhetri V. Sero-prevalence of transfusion transmitted infections among blood donors at CRRH, Gelephu, Bhutan. *J Med Sci Clin Res* 2018; 6. DOI: 10.18535/jmscr/v6i5.42.
63. Choudhary S, Choudhary K, Shekhawat K. Seropositivity of TTI (transfusion transmissible infections) among blood donors in blood bank of a district hospital in Northern Rajasthan: a 4 years record review. *Int J Appl Basic Med Res* 2018; 8: 142-148.
64. Giriyan SS, Sindhushree N. Seroprevalence of HIV among blood donors in KIMS blood bank, Hubballi, Karnataka, a tertiary care hospital. *Int J Clin Diagn Pathol* 2019; 2: 432-435.
65. Inamdar DP, Anuradha B. Seroprevalence of transfusion transmissible infections among blood donors at tertiary care hospital in southern Telangana-A 3 year cross sectional study. *Indian J Microbiol Res* 2018; 5: 446-450.
66. Kathpal N, Hippargi SB, Kumar A. Trends in seroprevalence of transfusion transmissible infections amongst the blood donors in tertiary care centre. *J Evid Based Med Healthc* 2019; 6: 1632-1636.
67. Khandekar SV, Chulki SF. Study of seroprevalence of HIV, HBV, HCV and syphilis among blood donors at tertiary care hospital in North Karnataka. *Natl J Community Med* 2018; 9: 667-670.
68. Kiran KA, Shikha S, Kashyap V. Association of transfusion transmitted infections with profile of donors at blood bank of a tertiary care hospital of Jharkhand. *IOSR Journal of Dental and Medical Sciences* 2021; 17: 27-30.
69. Lakshmikummar MT, Bettogowda S, Gaddi VJ, Hanumantharaya C. Prevalence of transfusion transmitted infections among blood donors: five years retrospective study from rural tertiary care hospital of South Karnataka. *Galore International Journal of Health Sciences and Research* 2019; 4.
70. Mahapatra S, Ray GK, Panigrahi R, Parida P. The incidence and spectrum of transfusion transmitted infections among the blood donors. *Int J Res Med Sci* 2018; 6: 904-907.
71. Mittal N, Rajput S, Kumar S, Das B. Transfusion transmissible infections (TTIS) trends and seroprevalence among blood donors at blood center of a tertiary care hospital: a 5-year study. *Paripex - Indian Journal of Research* 2019; 8.
72. Modi GB, Patel HS. Seroprevalence of transfusion transmitted infections among blood donors at district hospital of banaskantha in North Gujarat, India. *Int J Med Microbiol Trop Dis* 2018; 4: 122-126.
73. Omhare A, Purwar N, Singh SK, Rana U. Study of serological prevalence of transfusion transmissible infections among blood donors in a tertiary care hospital in North India. *Indian J Pathol Oncol* 2018; 5: 212-215.
74. Patel DD, Kusumgar RR. Seroprevalence of HIV, Hbsag, HCV and syphilis in blood donors at tertiary care center, Ahmadabad. *National Journal of Integrated Research in Medicine* 2018; 9: 72-75.
75. Puri S, Dhot P. Prevalence of HIV infection among blood donors at Tertiary Care Teaching Hospital of Uttar Pradesh. *Journal of Evolution of Medical and Dental Sciences* 2018; 7: 1513-1515.



76. Ray K, Roy H, Das M. Trends of transfusion transmissible infections among blood donors in a rural medical college of West Bengal, India. *Al Ameen Journal of Medical Sciences* 2018; 11: 93-100.
77. Sahu A, Panda M, Panda M. Trends of transfusion transmissible infections among the blood donors in a Tertiary Care Hospital. *Int J Med Sci Curr Res* 2019; 2: 476-484.
78. Solanki P, Yadav A, Likhar K. Seroprevalence of HIV in blood donors at tertiary care center, M.Y.H. Indore, India. *Int J Res Med Sci* 2019; 7: 183. DOI: 10.18203/2320-6012.ijrms20185377.
79. Sundaramoorthy R, Arunagiri R, Ganesan V, Perumal S, Tiruvanamalai R, Charles J. Seroprevalence of transfusion transmissible infections among blood donors by chemiluminescent assay in a tertiary care centre. *Journal of Infection in Developing Countries* 2018; 12: 31-36.
80. Umesh D, Aparna V, Padma S. Seroprevalence of transfusion-transmissible infectious agents (HIV, HBV, HCV, plasmodium species and treponema pallidum infections) among blood donors at a Tertiary Care Teaching Hospital in Chennai: changing trends over a period of five years. *Indian J Microb Res* 2018; 5: 31-37.
81. Varsha T, Ashwini K. Prevalence of transfusion transmissible infections in donors and utilization of blood and components in a tertiary care hospital. *J Evol Med Dental Sci* 2019; 8: 3125-3130.
82. Yadav UC, Sharma DC, Tomar A, Arya A, Kumar MU. Voluntary blood donation in a central state of India. *Medico Research Chronicles* 2018; 5: 141. DOI: 10.26838/MEDRECH.2018.5.2.401
83. Saraswati LD, Susanto H, Udiyono A, Ginandjar P, Winarno T. The prevalence of blood borne diseases in the community (A cross sectional study in the District of Semarang). *Indian J Public Health Res Develop* 2018; 9: 509-514.
84. Makroo RN, Choudhury N, Jagannathan L, et al. Multicenter evaluation of individual donor nucleic acid testing (NAT) for simultaneous detection of human immunodeficiency virus-1 & hepatitis B & C viruses in Indian blood donors. *Indian J Med Res* 2008; 127: 140-147.
85. Kumari S. Prevalence and trends of hepatitis B virus, hepatitis C virus, human immunodeficiency virus 1, 2 and syphilis infections among blood donors in a regional transfusion center in Punjab, India: a 3 years study. *Indian J Sex Transm Dis AIDS* 2020; 41: 22-29.
86. Tiwari B, Ghimire P, Kandel S, Rajkarnikar M. Seroprevalence of HBV and HCV in blood donors: a study from regional blood transfusion services of Nepal. *Asian J Transfus Sci* 2010; 4: 91-93.
87. Morawakage L. Prevalence of HIV and syphilis among voluntary blood donors at a Regional Blood Centre in Sri Lanka for three year period. *Sex Transm Infect* 2013; 89: A149.
88. Ramanayake RDH. 1260. Seroprevalence of transfusion-transmissible infections (HBV, HCV, HIV, and syphilis) among voluntary blood donors in Eastern Regional Blood Center Sri Lanka: a 4 years evaluation. *Open Forum Infect Dis* 2019; 6 (Suppl 2): S454. DOI: 10.1093/ofid/ofz360.1123.
89. Luksamijarulkul P, Thammatana N, Tiloklurs M. Seroprevalence of hepatitis B, hepatitis C and human immunodeficiency virus among blood donors, Phitsanulok Regional Blood Center, Thailand. *Southeast Asian J Trop Med Public Health* 2002; 33: 272-279.
90. Nantachit N, Robison V, Wongthanae A, Kamtorn N, Suriyanon V, Nelson KE. Temporal trends in the prevalence of HIV and other transfusion-transmissible infections among blood donors in northern Thailand, 1990 through 2001. *Transfusion* 2003; 43: 730-735.
91. Nuchprayoon C, Tanprasert S, Chumnijarakij T, Thanomchat S, O'Prasert B, Adulwijit S. Epidemiologic characteristics of blood donors with antibody to human immunodeficiency virus: Thailand. *Southeast Asian J Trop Med Public Health* 1995; 26: 98-103.
92. Carvalho MB, Hamerschlag N, Vaz RS, Ferreira OC Jr. Risk factor analysis and serological diagnosis of HIV-1/HIV-2 infection in a Brazilian blood donor population: validation of the World Health Organization strategy for HIV testing. *AIDS* 1996; 10: 1135-1140.
93. Sabino EC, Salles NA, de Almeida-Neto C, et al. Performance of parallel screening of Brazilian blood donors with two human immunodeficiency virus immunoassays: implications for sequential immunoassay testing algorithms in other countries. *Transfusion* 2011; 51: 175-183.
94. Andrade Neto JL, Pintarelli VL, Felchner PC, de Moraes RL, Nishimoto FL. HIV prevalence among blood donors in a blood bank in Curitiba (Brazil). *Braz J Infect Dis* 2002; 6: 15-21.
95. Deandrade A, Martelli CMT, Silva SAE, Santana CL, Zicker F. Blood-bank screening for HIV-infection: epidemiologic analysis in a low prevalence area. *Rev Inst Med Trop Sao Paulo* 1990; 32: 229-230.
96. Mondal R, Koley S, Aggarwal I, Kumar N. Seroprevalence of transfusion transmitted infections among blood donors and the trends of TTI in last three years in a tertiary care teaching hospital in Durgapur. *J Evid Based Med Healthc* 2019; 6: 252-256.
97. Pessoni LL, de Aquino EC, de Alcântara KC. Prevalence and trends in transfusion-transmissible infections among blood donors in Brazil from 2010 to 2016. *Hematol Transfus Cell Ther* 2019; 41: 310-315.
98. Reboucas K, Narici FM, Santos Junior MN, Neres NSM, Oliveira MV, Souza CL. Seroprevalence of transfusion-transmissible infectious diseases at a hemotherapy service located in southwest Bahia, Brazil. *Hematol Transfus Cell Ther* 2019; 41: 324-328.
99. Kupek E, Petry A. Changes in the prevalence, incidence and residual risk for HIV and hepatitis C virus in Southern Brazilian blood donors since the implementation of NAT screening. *Rev Soc Bras Med Trop* 2014; 47: 418-425.
100. Armstrong SAM, Gangam N, Chipman ML, Rootman DS. The prevalence of positive hepatitis B, hepatitis C, and HIV serology in cornea donors prescreened by medical and social history in Ontario, Canada. *Cornea* 1997; 16: 512-516.
101. Sumbu B, Longo-Mbenza B, Ahuka-Mundeké S, et al. Association between the viruses of the acquired immunodeficiency syndrome and the hepatitis C virus among young blood donors in Kinshasa: retrospective analysis of 10 years. *Transfus Clin Biol* 2018; 25: 26-34.
102. Ayala Gaytán JJ, Guerra Avalos FJ, Mora Brondo P, Casillas Romo A. Prevalence of viral markers for hepatitis B, C and human immunodeficiency virus in volunteer blood donors in Northeast Mexico. *Rev Gastroenterol Mex* 1997; 62: 250-253 [Article in Spanish].
103. Carreto-Velez MA, Corrada-Bravo T, Martinez-Magdalenó A. Seroprevalence of HBV, HCV and HIV in blood donors in Irapuato, Mexico. *Salud Publica Mex* 2003; 45 Suppl: S690-S693 [Article in Spanish].
104. Garcia-Montalvo BM. Seropositivity of HIV, HBV, HCV and *Treponema pallidum* in blood donors in southeast Mexico. *Rev Invest Clin* 2006; 58: 567-572 [Article in Spanish].
105. Arreguin V, Alvarez P, Simon JI, Valderrama JA, Macias AE. HIV in Mexican blood donors and estimated transfusional risk. *Rev Invest Clin* 2008; 60: 278-283 [Article in Spanish].
106. Jean Baptiste AE, Chevalier MS, Polo E, Noel E, Hulland EN, Archer WR. Trends in hepatitis B and hepatitis C seroprevalence among blood donors – Haiti, 2005-2014. *ISBT Sci Ser* 2018; 13: 150-157.
107. Zou S, Dorsey KA, Notari EP, et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. *Transfusion* 2010; 50: 1495-1504.
108. León G, Hernández T, Quiros AM, Maio A, García L. How to reduce the prevalence of HIV-positive blood donors. *Invest Clin* 1998; 39: 307-321.
109. Quintas E, Cogle A, Caetano F, Dias C, Sebastião A. Trends in human immunodeficiency virus type 1/2 prevalence among young adult blood donors, from 2011 to 2016, attending a private clinic in Angola. Retrospective study of prevalence. *J Infect Dis Pathog* 2018; 1.
110. Yooda AP, Sawadogo S, Soubeiga ST, et al. Residual risk of HIV, HCV, and HBV transmission by blood transfusion between 2015

- and 2017 at the Regional Blood Transfusion Center of Ouagadougou, Burkina Faso. *J Blood Med* 2019; 10: 53-58.
111. Nagalo MB, Sanou M, Bisseye C, et al. Seroprevalence of human immunodeficiency virus, hepatitis B and C viruses and syphilis among blood donors in Koudougou (Burkina Faso) in 2009. *Blood Transfus* 2011; 9: 419-424.
  112. Eboumbou Moukoko CE, Ngo Sack F, Essangui Same EG, Mbangue M, Lehman LG. HIV, HBV, HCV and *T. pallidum* infections among blood donors and Transfusion-related complications among recipients at the Laquintinie hospital in Douala, Cameroon. *BMC Hematol* 2014; 14: 5. DOI: 10.1186/2052-1839-14-5.
  113. Fouelifack Ymele F, Keugoung B, Fouedjio JH, Kouam N, Mendiabi S, Dongtsa Mabou J. High rates of hepatitis B and C and HIV infections among blood donors in Cameroon: a proposed blood screening algorithm for blood donors in resource-limited settings. *J Blood Transfus* 2012; 2012: 458372. DOI: 10.1155/2012/458372.
  114. Sanou M. Double speed transfusion in Burkina Faso: results of the Elisa 4<sup>th</sup> generation tests versus Determine™ HIV<sub>1/2</sub> of blood donors presumed to be seroconverting at national blood transfusion center. *Acta Sci Microbiol* 2018; 1: 26-29.
  115. Kengne M, Tsata DCW, Ndongue T, Nwobegahay JM. Prevalence and risk factors of HTLV-1/2 and other blood borne infectious diseases among blood donors in Yaounde Central Hospital, Cameroon. *Pan Afr Med J* 2018; 30: 125. DOI: 10.11604/pamj.2018.30.125.14802.
  116. Noubiap JJ, Joko WY, Nansseu JR, Tene UG, Siaka C. Seroepidemiology of human immunodeficiency virus, hepatitis B and C viruses, and syphilis infections among first-time blood donors in Edéa, Cameroon. *Int J Infect Dis* 2013; 17: e832-837. DOI: 10.1016/j.ijid.2012.12.007.
  117. Mbendi Nlombi C, Longo-Mbenza B, Mbendi Nsukini S, Muyembe Tamfum JJ, Situakibanza Nanituma H, Vangu Ngoma D. Prevalence of HIV and HBSAG in blood donors. Residual risk of transfusion transmission for blood receivers in East-Kinshasa, Democratic Republic of Congo. *Med Trop (Mars)* 2001; 61: 139-142.
  118. Xu T, Yi ZM, Luo JM, et al. Prevalence and trends of transfusion-transmissible infections among blood donors in Southwest China. *J Public Health (Oxf)* 2019; 41: 55-61.
  119. David L, Gael B, Christian P, Olivier M, Marie-France P. Risk factors of the transmission of the HIV, hepatitis B and C and syphilis among blood donors at the Saint Luc General Hospital of Kisanu, Democratic Republic of Congo. *J HIV Retrovirus* 2018; 4: 18. DOI: 10.21767/2471-9676.100050.
  120. Ilumbulumbu MK, Ketha JK, Tshimanga VK, et al. High prevalence of transfusion-transmissible infections among volunteer blood donors in rural area of Eastern Democratic Republic of the Congo (DRC). *Arch Curr Res Int* 2018; 14: 1-8.
  121. Seri B, Minga A, Gabillard D, et al. Twenty-year evolution of hepatitis B virus and human immunodeficiency virus prevalence and incidence in voluntary blood donors in Cote d'Ivoire. *Open Forum Infect Dis* 2018; 5: ofy060. DOI: 10.1093/ofid/ofy060.
  122. Dray X, Dray-Spira R, Bronstein JA, Mattered D. Prevalences of HIV, hepatitis B and hepatitis C in blood donors in the Republic of Djibouti. *Med Trop (Mars)* 2005; 65: 39-42.
  123. Noboa RJ, Pazmiño MJ, Diaz MM, Maldonado VP, Vallejo RS. Profile of blood donors with serologic test reactive in hospital metropolitano in Quito-Ecuador from January 2016 to December 2018. *HemaSphere* 2019; 3: 359. DOI: 10.1097/01.HS9.0000561532.97706.50
  124. Keleta YT, Achila OO, Haile AW, et al. Seroprevalence of transfusion transmitted infections among blood donors in Gash Barka Zonal Blood Transfusion Center, Barentu, Eritrea, 2014 through 2017. *BMC Hematol* 2019; 19: 5. DOI: 10.1186/s12878-019-0136-5.
  125. Gezahegn M, Woldemichael K, Godesso A. HIV sero-prevalence trend among blood donors in Jimma University Specialized Hospital, Southwest Ethiopia. *Ethiop J Health Sci* 2012; 22: 37-43.
  126. Mohammed Y, Bekele A. Seroprevalence of transfusion transmitted infection among blood donors at Jijiga blood bank, Eastern Ethiopia: retrospective 4 years study. *BMC Res Notes* 2016; 9: 129. DOI: 10.1186/s13104-016-1925-6.
  127. Sentjens RE, Sisay Y, Vrieling H, et al. Prevalence of and risk factors for HIV infection in blood donors and various population subgroups in Ethiopia. *Epidemiol Infect* 2002; 128: 221-228.
  128. Ramos JM, Tissiano G, Fano H, et al. Prevalence of positive HIV, HBV, HCV and treponemal tests in blood donors in a rural hospital in southern Ethiopia. *J Clin Virol* 2016; 77: 60-62.
  129. Rahlenbeck SJ, Yohannes G, Molla K, Reifen R, Assefa A. Infection with HIV, syphilis and hepatitis B in Ethiopia: a survey in blood donors. *Int J STD AIDS* 1997; 8: 261-264.
  130. Tessema B, Yismaw G, Kassu A, et al. Seroprevalence of HIV, HBV, HCV and syphilis infections among blood donors at Gondar University Teaching Hospital, Northwest Ethiopia: declining trends over a period of five years. *BMC Infect Dis* 2010; 10: 111. DOI: 10.1186/1471-2334-10-111.
  131. Ataro Z, Urgessa F, Washun T. Prevalence and trends of major transfusion transmissible infections among blood donors in Dire Dawa Blood Bank, Eastern Ethiopia: retrospective study. *Ethiop J Health Sci* 2018; 28: 701-710.
  132. Siraj N, Achila OO. Seroprevalence of transfusion-transmissible infections among blood donors at National Blood Transfusion Service, Eritrea: a seven-year retrospective study. *BMC Infect Dis* 2018; 18: 264. DOI: 10.1186/s12879-018-3174-x.
  133. Berhanu S, Abebaw S, Digissie A. Transfusion-transmissible infections among voluntary blood donors at Debre Tabor Blood Bank, North West Ethiopia: a three years retrospective study. *Health Care Curr Rev* 2018; 6: 2. DOI: 10.4172/2375-4273.1000236.
  134. Deressa T, Birhan W, Enawgaw B, et al. Proportion and predictors of transfusion-transmissible infections among blood donors in North Shewa Zone, Central North Ethiopia. *PLoS One* 2018; 13: e0194083. DOI: 10.1371/journal.pone.0194083.
  135. Teklemariam Z, Mitiku H, Weldegebreal F. Seroprevalence and trends of transfusion transmitted infections at Harar blood bank in Harari regional state, Eastern Ethiopia: eight years retrospective study. *BMC Hematol* 2018; 18: 24. DOI: 10.1186/s12878-018-0115-2.
  136. Negash M, Ayalew M, Geremew D, Workneh M. Seroprevalence and associated risk factors for HIV, hepatitis B and C among blood donors in South Gondar District Blood Bank, Northwest Ethiopia. *BMC Infect Dis* 2019; 19: 430. DOI: <https://doi.org/10.1186/s12879-019-4051-y>.
  137. Shiferaw E, Tadilo W, Melkie I, Shiferaw M. Sero-prevalence and trends of transfusion-transmissible infections among blood donors at Bahir Dar district blood bank, northwest Ethiopia: a four year retrospective study. *PLoS One* 2019; 14: e0214755. DOI: 10.1371/journal.pone.0214755.
  138. Teklemariam Z, Mitiku H, Weldegebreal F. Seroprevalence and trends of transfusion transmitted infections at Harar blood bank in Harari regional state, Eastern Ethiopia: eight years retrospective study. *BMC Hematol* 2018; 18: 24. DOI: 10.1186/s12878-018-0115-2.
  139. Tigabu A, Engda T, Mekonnen F. Seroprevalence of transfusion transmissible viral infections (HIV, HBV and HCV) among voluntary blood donors at University of Gondar Comprehensive Specialized Hospital, Gondar; Northwest Ethiopia. *BMC Infect Dis* 2019; 19: 393. DOI: 10.1186/s12879-019-3950-2.
  140. Degefa B, Gebreyesus T, Gebremedhin Z, et al. Prevalence of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus among blood donors of Mekelle blood bank, Northern Ethiopia: a three-year retrospective study. *J Med Virol* 2018; 90: 1724-1729.
  141. Berteau F, Mention J, Tissedre J, et al. Evaluation of the seroprevalence of human immunodeficiency virus (HIV) and human T-cell lymphotropic virus (HTLV) in Haut Ogooué Province in Gabon

- in pregnant women and blood donor control groups. *Bull Soc Pathol Exot* 1993; 86: 12-15 [Article in French].
142. Bisseye C, Mombo LE, Bie SMM, et al. Trends of blood-borne infectious diseases in a rural blood donation center of southeast Gabon (Koula-Moutou). *Pan Afr Med J* 2018; 31: 81. DOI: 10.11604/pamj.2018.31.81.16331.
  143. Ngassaki-Yoka CD, Ndong JMN, Bisseye C. ABO, Rhesus blood groups and transfusion-transmitted infections among blood donors in Gabon. *Sudan J Med Sci* 2018; 13: 12-21.
  144. Awuah M, Ahmed S, Edzeamey FJ, et al. Trend of donor rejection due to the incidence of hepatitis B and C viruses, human immunodeficiency virus (HIV 1&2) and *Treponema pallidum* in Ghana: a retrospective study. *Int J Res Rep Hematol* 2019; 2: 1-10.
  145. Muktar AT, Yidana A, Wombeogo M, Weikam EW. Prevalence and trends of HIV and syphilis among blood donors in the northern region of Ghana; a five-year retrospective study. *World* 2019; 4: 65-73.
  146. Xie DD, Li J, Chen JT, et al. Seroprevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and *Treponema pallidum* infections among blood donors on Bioko Island, Equatorial Guinea. *PLoS One* 2015; 10: e0139947. DOI: 10.1371/journal.pone.0139947.
  147. Moore A, Herrera G, Nyamongo J, et al. Estimated risk of HIV transmission by blood transfusion in Kenya. *Lancet* 2001; 358: 657-660.
  148. Bartonjo G, Oundo J. Prevalence and associated risk factors of transfusion transmissible infections among blood donors at Regional Blood Transfusion Center Nakuru and Tenwek Mission Hospital, Kenya. *Pan Afr Med J* 2019; 34: 31. DOI: 10.11604/pamj.2019.34.31.17885.
  149. Moses LCO, Gicheru MM, Kabiru EW. HIV prevalence among secondary school student blood donors in Nairobi County, Kenya. *Int J Sci Res* 2018; 7: 314-317.
  150. Onyango CG, Ogonda L, Guyah B, et al. Seroprevalence and determinants of transfusion transmissible infections among voluntary blood donors in Homabay, Kisumu and Siaya counties in western Kenya. *BMC Res Notes* 2018; 11: 171. DOI: 10.1186/s13104-018-3276-y.
  151. Shan H, Bartonjo G, Oundo J, Ng'ang'a Z. Prevalence and associated risk factors of transfusion transmissible infections among blood donors at Regional Blood Transfusion Center Nakuru and Tenwek Mission Hospital, Kenya. *Transfusion* 2019; 34: 31.
  152. Zachariah R, Harries AD, Nkhoma W, et al. HIV prevalence and demographic risk factors in blood donors. *East Afr Med J* 2002; 79: 88-91.
  153. Mabvakure BM, Scheepers C, Garrett N, et al. Positive selection at key residues in the HIV envelope distinguishes broad and strain-specific plasma neutralizing antibodies. *J Virol* 2019; 93: e01685-18. DOI: 10.1128/JVI.01685-18.
  154. Diarra A, Kouriba B, Baby A, Murphy E, Lefrere JJ. HIV, HCV, HBV and syphilis rate of positive donations among blood donations in Mali: lower rates among volunteer blood donors. *Transfus Clin Biol* 2009; 16: 444-447.
  155. Jary A, Dienta S, Leducq V, et al. Seroprevalence and risk factors for HIV, HCV, HBV and syphilis among blood donors in Mali. *BMC Infect Dis* 2019; 19: 1064. DOI: 10.1186/s12879-019-4699-3.
  156. Mavnyengwa RT, Mukesi M, Chipare I, Shoombe E. Prevalence of human immunodeficiency virus, syphilis, hepatitis B and C in blood donations in Namibia. *BMC Public Health* 2014; 14: 424. DOI: 10.1186/1471-2458-14-424.
  157. Ejele OA, Nwauche CA, Erhabor O. Seroprevalence of HIV infection among blood donors in Port Harcourt, Nigeria. *Nigerian J Med* 2005; 14: 287-289.
  158. Dirisu JO, Alli TO, Adegoke AO, Osazuwa F. A Survey of prevalence of serum antibodies to human immunodeficiency deficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) among blood donors. *North Am J Med Sci* 2011; 3: 35-38.
  159. Kulharni AG, Mba EC, Seidl S, Skhnl P. Prevalence of human immunodeficiency virus antibodies in northern Nigerian blood donors. *Transfusion* 1987; 27: 216-217.
  160. Umolu PI, Okoror LE, Orhue P. Human immunodeficiency virus (HIV) seropositivity and hepatitis B surface antigenemia (HBSAG) among blood donors in Benin city, Edo state, Nigeria. *Afr Health Sci* 2005; 5: 55-58.
  161. Alao OO, Okwori EE. Sero-prevalence of HIV infection among blood donors in a secondary health institution in the middle belt of Nigeria. *Int J Hematol* 2009; 6.
  162. Ajayi BB, Moses AE, Ezimah ACU, Adelowo KA, Bukbuk DN, Baba MM. HIV prevalence among blood donors in University of Maiduguri Teaching Hospital (UMTH): a ten year experience. *Int J Virol* 2007; 3: 35-40.
  163. Olajubu FA, Osinupebi OA, Deji-Agboola M, Jagun EO. Seroprevalence of HIV among blood donors, antenatal women and other patients in a tertiary hospital in Nigeria. *Braz J Infect Dis* 2009; 13: 280-283.
  164. Ogunkolo OF, Adenaike FA, Amballi AA, Taiwo O. Prevalence of HIV positive blood donors among screened volunteers who satisfied the criteria for blood donation in a semi-urban Nigeria population. *Afr J Biotechnol* 2006; 5: 553-554.
  165. Nnodu O, Odunukwe N, Anni D. Misleading high HIV seroprevalence among blood donors. The trend in a specialist hospital blood bank in Lagos, Nigeria. *Int Soc Haematol* 2003: 247-251.
  166. Oronsaye FE, Oronsaye JI. Prevalence of HIV-positives and hepatitis B surface antigen-positives among donors in the University of Benin Teaching Hospital, Nigeria. *Tropical Doctor* 2004; 34: 159-160.
  167. Akpulu S, Adamu M, Oledinma S, Yaro E, Ajayi I. Prevalence of transfusion transmissible infection among blood donors attending Hajiya Gambo Sawaba General Hospital Zaria. *Nigerian Biomedical Science Journal* 2017; 14: 24-37.
  168. Kapse V, Agrawal A, Bhaskar V, Gahine R. Seroprevalence of transfusion transmissible infections among blood donors in a Tertiary Care Centre: eight years study. *Int J Sci Res* 2019; 8: 11-13.
  169. Ojo OV. Seroprevalence of human immunodeficiency virus (HIV) among blood donors in Tertiary Health Care Centre in Taraba State, Nigeria. *EC Emergency Medicine and Critical Care* 2019; 3: 1-5.
  170. Okoroiwu HU, Asemota EA. Blood donors deferral prevalence and causes in a tertiary health care hospital, southern Nigeria. *BMC Health Serv Res* 2019; 19: 510. DOI: 10.1186/s12913-019-4352-2.
  171. Ugwu A, Madu A, Efobi C, Ibegbulam O. Pattern of blood donation and characteristics of blood donors in Enugu, Southeast Nigeria. *Nigerian J Clin Pract* 2018; 21: 1438-1443.
  172. Yambasu EE, Reid A, Owiti P, Manzi M, Murray MJS, Edwin AK. Hidden dangers-prevalence of blood borne pathogens, hepatitis B, C, HIV and syphilis, among blood donors in Sierra Leone in 2016: opportunities for improvement: a retrospective, cross-sectional study. *Pan Afr Med J* 2018; 30: 44.
  173. Vermeulen M, Swanevelder R, Chowdhury D, et al. Prevalence of HIV and Hepatitis B and C viruses in South African Blood Donors, 2012-2014. *Transfusion* 2015; 55: 181A-182A.
  174. Vermeulen M, Swanevelder R, Chowdhury D, et al. Use of blood donor screening to monitor prevalence of HIV and hepatitis B and C viruses, South Africa. *Emerg Infect Dis* 2017; 23: 1560-1563.
  175. Mohammed BA, Badneen MA, Gibreel MO, Othman SA. Prevalence of transfusion-transmissible infections among blood donors in Port Sudan. *Egypt J Haematol* 2019; 44: 72-76.
  176. Valerian DM, Mauka WI, Kajeguka DC, et al. Prevalence and causes of blood donor deferrals among clients presenting for blood donation in northern Tanzania. *PLoS One* 2018; 13: e0206487. DOI: 10.1371/journal.pone.0206487.
  177. Soderberg S, Temihango W, Kadete C, et al. Prevalence of HIV-1 infection in rural, semi-urban and urban villages in southwest Tanzania: estimates from a blood-donor study. *AIDS* 1994; 8: 971-976.

178. Matee MI, Magesa PM, Lyamuya EF. Seroprevalence of human immunodeficiency virus, hepatitis B and C viruses and syphilis infections among blood donors at the Muhimbili National Hospital in Dar es Salaam, Tanzania. *BMC Public Health* 2006; 6: 21. DOI: <https://doi.org/10.1186/1471-2458-6-21>.
179. Haukenes G, Shao J, Mhalu F, Nome S, Sam NE. The AIDS epidemic in Tanzania: rate of spread of HIV in blood donors and pregnant women in Dar es Salaam. *Scand J Infect Dis* 1992; 24: 701-706.
180. Mapako T, Mvere DA, Chitiyo ME, Rusakaniko S, Postma MJ, van Hulst M. Human immunodeficiency virus prevalence, incidence, and residual transmission risk in first-time and repeat blood donations in Zimbabwe: implications on blood safety. *Transfusion* 2013; 53 (10 Pt 2): 2413-2421.
181. Aymard JB, Janot C, Contal P, Linel C, Monange G, Streiff F. Epidemiologic study of HIV serology in blood donors from 5 departments in northeastern France (1985-1989). *Rev Fr Transfus Hémobiol* 1989; 32: 421-429.
182. Velati C, Romano L, Piccinini V, et al. Prevalence, incidence and residual risk of transfusion-transmitted hepatitis C virus and human immunodeficiency virus after the implementation of nucleic acid testing in Italy: a 7-year (2009-2015) survey. *PLoS One* 2018; 16: 422-432.
183. Caspari G, Beyer J, Schunter F, Knüver-Hopf J, Schmitt H. HIV-specific antibody among voluntary blood donors in lower saxony (FRG). *Blut* 1987; 55: 181-187.
184. Vucetic D, Jovicic M, Maslovacic I, et al. Transfusion-transmissible infections among Serbian blood donors: declining trends over the period 2005-2017. *Blood Transfus* 2019; 17: 336-346.
185. Altes A, Muniz-Diaz E, Madoz P, Verger G, Martino R, Puig L. Blood donors seropositive for type 1 human immunodeficiency virus (HIV-1). Epidemiologic characteristics and clinical course. *Sangre* 1995; 40: 269-274.
186. Coskun O, Gul C, Erdem H, Bedir O, Eyigun C. Prevalence of HIV and syphilis among Turkish blood donors. *Ann Saudi Med* 2008; 28: 470. DOI: [10.5144/0256-4947.2008.470](https://doi.org/10.5144/0256-4947.2008.470).
187. Dayan S, Tekin A, Tekin R, et al. HBsAg, anti-HCV, anti-HIV 1/2 and syphilis seroprevalence in healthy volunteer blood donors in southeastern Anatolia. *J Infect Develop Countries* 2013; 7: 665-669.
188. Kader Ç, Erbay A, Birengel S, Gürbüz M. Seroprevalence of hepatitis B virus, hepatitis C virus, human immunodeficiency virus infections and syphilis in blood donors. *Klinik Dergisi* 2010; 23: 95-99.
189. Tigen ET, Doğru A, Karadağ FY. Hepatitis B, Hepatitis C and human immunodeficiency virus prevalences among first time blood donors in Istanbul, Turkey, 2004-2011. *Transfusion and Apheresis Science* 2015; 53: 176-179.
190. Altuglu I, Sayiner AA, Erensoy S, Zeytinoglu A, Bilgiç A. Screening for human immunodeficiency virus type 1 and 2 in a Turkish blood donor population. *Int J Infect Dis* 1998; 2: 202-204.
191. Afsar I, Gungor S, Sener A, Yurtsever S. The prevalence of HBV, HCV and HIV infections among blood donors in Izmir, Turkey. *Indian J Med Microbiol* 2008; 26: 288-289.
192. Acar A, Kemahli S, Altunay H, et al. HBV, HCV and HIV seroprevalence among blood donors in Istanbul, Turkey: how effective are the changes in the national blood transfusion policies? *Braz J Infect Dis* 2010; 14: 41-46.
193. Gunduz T, Mumcuoglu I, Guray M. Evaluation of hepatitis B surface antigen, anti-hepatitis C virus and anti-human immunodeficiency virus antibodies and syphilis seropositivity in blood donors: Six years' seropositivity. *Int J Clin Pharmacol Res* 2005; 25: 155-158.
194. Oner S, Yapici G, Sasmaz CT, Kurt AO, Bugdayci R. Hepatitis B, hepatitis C, HIV, and VDRL seroprevalence of blood donors in Mersin, Turkey. *Turkish J Med Sci* 2011; 41: 335-341.
195. Kocak N, Hepgul S, Ozbayburtlu S, et al. Trends in major transfusion-transmissible infections among blood donors over 17 years in Istanbul, Turkey. *J Int Med Res* 2004; 32: 671-675.
196. Altindis M, Yilmaz S, Dikengil T, Acemoglu H, Hosoglu S. Seroprevalence and genotyping of hepatitis B, hepatitis C and HIV among healthy population and Turkish soldiers in Northern Cyprus. *World J Gastroenterol* 2006; 12: 6792-6796.
197. Yildiz SM, Candevir A, Kibar F, et al. Hepatitis B, Hepatitis C, Human immunodeficiency virus and syphilis frequency among blood donors: a single center study. *Transfus Apher Sci* 2015; 53: 308-314.
198. Eissa SA, Abdel Meguid LM, Ebeid SM, Abou Elfetouh RM, Abdel Moneim GM. National Cancer Institute Experience in Healthy Egyptian Blood Donors as Regards Blood Group Frequencies and Seroprevalence of Hepatitis B Virus, Hepatitis C Virus & HIV: 10 Year Evaluation. *J Egypt Natl Cancer Institute* 2007; 19: 71-76.
199. Senosy SA. Prevalence of HIV among blood donors at Beni-Suef University Hospital Blood Bank, Egypt. *J Egypt Public Health Assoc* 2015; 90: 157-160.
200. Al-alwani HR. Seropositive prevalence of transfusion transmitted infections among blood donors in Al-Anbar province after war displacement period. *J Pharm Sci Res* 2018; 10: 3333-3335.
201. Al-Nafakh RT, Al-Sherees HAA, Al-Charrakh AH. Seroprevalence of HBV, HCV, and HIV among Blood Donors in Main Blood Bank in Najaf Province, Iraq. *Indian J Public Health Res Develop* 2019; 10: 385-390.
202. Butt KK, Shafiq F, Yousaf MA. Prevalence of HIV, ANTI-HCV, HBsAg and VDRL positive cases in blood donors of bhatti international Trust Hospital, Kasur. *Pakistan J Med Health Sci* 2013; 7: 662-663.
203. Moiz B, Moatter T, Shaikh U, et al. Estimating window period blood donations for human immunodeficiency virus Type 1, hepatitis C virus, and hepatitis B virus by nucleic acid amplification testing in Southern Pakistan. *Transfusion* 2014; 54: 1652-1659.
204. Siddiqui MMA, Khan MM, Niazi MZIK. Prevalence of hepatitis C, hepatitis B and human immunodeficiency virus infection among blood donors at Fatimid Center Multan. *Medical Forum Monthly* 2008; 19: 26-31.
205. Safi SZ, Afzal MS, Waheed Y, et al. Seroprevalence of hepatitis C and human immunodeficiency viruses in blood donors of north-western Pakistan. *Asian Biomedicine* 2011; 5: 389-392.
206. Asif N, Khokhar N, Ilahi F. Seroprevalence of HBV, HCV and HIV infection among voluntary non remunerated and replacement donors in northern Pakistan. *Pakistan J Med Sci* 2004; 20: 24-28.
207. Akhter N, Fatima S, Batool Y, Samad A, Fayaz N, Khan Z. Seroprevalence of Transfusion Transmitted Infections among Healthy Donors in a Tertiary Care Hospital in Southern Punjab, Pakistan. *Biomedica* 2018; 34: 168-172.
208. Ali M, Karim F. Monitoring response rate of blood donors concerning positive screening tests for HIV and syphilis: an institutional approach toward donor hemovigilance. *Egyptian J Haematol* 2018; 43: 217-221.
209. Aslam M, Qureshi U, Anasari M. Prevalence of viral hepatitis & HIV infections among blood donors at Amna Thalassemia Center Multan. *Pakistan J Med Health Sci* 2019; 13: 653-656.
210. Awan SA, Junaid A, Sheikh S. Transfusion transmissible infections: maximizing donor surveillance. *Cureus* 2018; 10: e3787. DOI: [10.7759/cureus.3787](https://doi.org/10.7759/cureus.3787).
211. Rauf R, Cheema A. Potential risk of transfusion-transmissible infections among blood donors in district Faisalabad of Pakistan. *Clin Med (Lond)* 2019; 19 (Suppl 3): 27. DOI: [10.7861/clinmedicine.19-3s-s27](https://doi.org/10.7861/clinmedicine.19-3s-s27)
212. Zeeshan M, Anwar F, Shah IA, Shah M. Prevalence of HBV, HCV, HIV and syphilis in blood donor at Mardan Medical complex, Khyber Pakhtunkhwa, Pakistan. *Int J Biosci* 2018; 12: 297-303.
213. Khattak MF, Salamat N, Bhatti FA, Qureshi TZ. Seroprevalence of hepatitis B, C and HIV in blood donors in northern Pakistan. *J Pak Med Assoc* 2002; 52: 398-402.
214. Maayan S, Shinar E, Aefani M, Soughayer M, Alkhoudary R, Barshany S, et al. HIV-1 prevalence among Israeli and Palestinian blood donors. *AIDS* 1994; 8: 133-134.

215. Elbjeirami W, Al-Jedani H, Arsheed N, et al. Prevalence and trends of HBV, HCV, and HIV serological and NAT markers and profiles in Saudi blood donors. *Haematologica* 2015; 100: 631.
216. El-Hazmi MM. Prevalence of HBV, HCV, HIV-1, 2 and HTLV-I/II infections among blood donors in a teaching hospital in the central region of Saudi Arabia. *Saudi Med J* 2004; 25: 26-33.
217. Alaidarous M, Choudhary RK, Waly MI, et al. The prevalence of transfusion-transmitted infections and nucleic acid testing among blood donors in Majmaah, Saudi Arabia. *J Infect Public Health* 2018; 11: 702-706.
218. Saghir SAM, Al-Hassan FM, Alsalahi OSA, Alhariry AEA-A, Baqir HS. Frequencies of HBV, HCV, HIV, and syphilis markers among blood donors: a hospital-based study in Hodeidah, Yemen. *Trop J Pharma Res* 2012; 11: 132-136.
219. Du G, Li X, Musa TH, et al. The nationwide distribution and trends of hepatitis C virus genotypes in mainland China. *J Med Virol* 2019; 91: 401-410.
220. Al-Zubiery TK, Alsumairy H, Alharazi T, Al-Zubeiry A, Jabir AA, Muckbil MJ. Seroprevalence of human immunodeficiency virus (HIV) among blood donors attending national blood transfusion and research center in Sana'a City, Yemen: warning sign. *Int STD Res Rev* 2018; 7: 1-7.
221. Adusei KA, Owusu-Ofori A. Prevalence of Plasmodium parasitaemia in blood donors and a survey of the knowledge, attitude and practices of transfusion malaria among health workers in a hospital in Kumasi, Ghana. *PLoS One* 2018; 13: e0206303. DOI: 10.1371/journal.pone.0206303.
222. Esmaili HHG, Mankhian A, Poumehdi Broujeni M. Seroepidemiological survey of hepatitis B, C, HIV and syphilis among blood donors in Bushehr-Iran. *Iranian South Med J* 2009; 11: 183-190.
223. Jabbari H, Karami S, Fattahi F, Jam S, Mohraz M. Seroprevalence of human immunodeficiency virus, hepatitis B and C viruses among blood donors in Chabahar Iran. *Int J Infect Dis* 2008; 12: e424. DOI: <https://doi.org/10.1016/j.ijid.2008.05.1242>.
224. Kasraian L, Torab-Jahromi S. The frequency of HIV infection in blood donors in Shiraz blood transfusion organization from 1998 to 2002. *J Adv Med Biomed Res* 2003; 11: 49-52.
225. Kasraian L. Survey the rate of blood donors loss due to unconfirmed Elisa test in blood transfusion organization in Fars province. *J Guilan Univ Med Sci* 2008; 17: 80-87.
226. Kasraian L, Tavasoli A. Positivity of HIV, hepatitis B and hepatitis C in patients enrolled in a confidential self-exclusion system of blood donation: a cross-sectional analytical study. *Sao Paulo Med J* 2010; 128: 320-323.
227. Kasraian L, Torab Jahromi A, Farhangiz B. A survey of epidemiological status and prevalence rate of HIV cases in blood donors during 2005 in Shiraz blood transfusion organization. *Vox Sanguinis* 2006; 91: 40.
228. Azadbakht M, Ardakani MT, Delirakbariazar M, et al. Seroprevalence and trend of HBV, HCV, and HIV infections among blood donors of Fars province, Iran (2006-2018). *Ethiop J Health Sci* 2020; 30: 397-408.
229. Mardani AGS, Shahsavarani M, Sahami Zibafar M, Mardani H. Demographic characteristics of blood transmitted viral infections in Qom blood donors after Bam earthquake. *Iranian J Infect Dis Trop Med* 2010; 15: 31-36.
230. Bani Aghil S, Abbasi S, Arab M, Seyedein M. The prevalence of HCV, HBV, HIV in blood donors of Golestan province (2006-2008). *Med Lab J* 2009; 3.
231. Kazeminejad V, Azarhoush R, Mowlana A, Dehbashi G. Frequency of hepatitis B virus, hepatitis C virus and human immunodeficiency virus in blood donors and patients in Gorgan blood transfusion organization in 2003. *Journal of Gorgan University of Medical Sciences* 2005; 7: 84-86.
232. Hosseini M, Baniaghil S, Mahmoodi E, Bagheri Sani Y, Dabhashi G. Prevalence of HIV, HCV, HBV in blood donors of Golestan province, Iran, 2012-2013. *Med Lab J* 2015; 9: 116-121.
233. Taheri Azbarmi Z, Nouri S, Joukar F, et al. Transfusion transmitted diseases in Rasht blood donors. *Sci J Iranian Blood Transfus Organ* 2008; 4: 337-343.
234. Reza-Zadeh MMKK, Mohammadi A, Zandevakili H, Lotfi A, Bahrami H, Abbasi B. Prevalence of human immunodeficiency, hepatitis B and hepatitis C viruses in the first time, repeat and regular donors in blood transfusion center, Hamadan, 2004-2005. *Iranian J Infect Dis Trop Med* 2006; 11: 55-60.
235. Boustani H, Anvari E, Saiadi Sartang S, Omidi M, Rostami E, Mohamadi Z. Prevalence of HIV, hepatitis B and C infections among volunteer blood donors at the blood transfusion center of Ilam city, Iran. *J Basic Res Med Sci* 2017; 4: 4-8.
236. Maleki FHS, Mahdavi Z, Azizian M, Amraei M. Prevalence of viral infection of blood donors in Ilam blood transfusion center. *J Basic Res Med Sci* 2014; 1: 51-55.
237. Mohammadi Tahroodi F, Abdyzadani N, Shakeri F, et al. The prevalence of hepatitis B, hepatitis C and AIDS in blood donors in Ilam province: a retrospective study. *Iranian J Virol* 2018; 12: 32-39.
238. Ebrahimian Z, Fazilati M, Akbari N, Hariri M, Fatehi Far M. Correlation of deferral rate with the frequency rate of viral markers of HBV, HCV and HIV in blood supplies during 2004 to 2009. *Sci J Iran Blood Transfus Organ* 2011; 8: 130-136.
239. Masaeli ZJMR, Magsudlu M. A comparison of seroprevalence of blood-borne infections among regular, sporadic, and first-time blood donors in Isfahan. *Sci J Iran Blood Transfus Organ* 2006; 2: 301-307.
240. Pourazar AAN, Hariri M, Yavari F, Akbari Sh. Evaluation of demographic profiles and prevalence of major viral markers in first time vs repeat blood donors in Esfahan. *Sci J Iran Blood Transfus Organ* 2006; 2: 323-329.
241. Moniri R, Mosayebi Z, Mousavi G. Seroprevalence of cytomegalovirus, hepatitis B, hepatitis C and human immunodeficiency virus antibodies among volunteer blood donors. *Iranian J Public Health* 2004; 33: 38-42.
242. Askari M, Beygzadeh A, Mohamadpour M. The prevalence of transfusion transmitted infections among blood donors in Kerman, Iran. *Journal of Kerman University of Medical Sciences* 2015; 22: 669-676.
243. Etminan A, Askari SMS. The association between the prevalence of transfusion transmitted infections and characteristics of infected blood donors in Kerman, Iran. *Journal of Kerman University of Medical Sciences* 2019; 26: 377-383.
244. Kolivand M, Hashemimehr A, Safari S. Assessment of HIV prevalence in blood donors in Kermanshah province, 2005. *J Kermanshah Univ Med Sci* 2011; 14: 353-356.
245. Kolivand M, Hashemimehr AS, Safari S. Assessment of HIV prevalence in blood donors in Kermanshah province, 2005. *J Kermanshah Univ Med Sci* 2011; 14: 353-356.
246. Aghajanipoor K, Zandieh T. Seroepidemiological investigation of hepatitis B, C and HIV virus in safe blood donors of Babol Blood Transfusion Center. *Sci J Iranian Blood Transfus Organ* 2006; 2: 339-341.
247. Nour Kojory S, Alaoddowleie H, Seddighian F. Efficacy of confidential self-exclusion and failed systems on blood donation safety in Sari and Behshahr blood donors. *Sci J Iranian Blood Transfus Organ* 2007; 4: 153-158.
248. Rezaie M, Khaleghian A. Prevalence of hepatitis B, hepatitis C and HIV in blood donors in Semnan Province (Iran) from 2011 to 2015. *Koomesh* 2016; 17: 501-508.
249. Attarchi Z, Ghafouri M, Hajibaygi B, Assari S, Alavian S. Donor deferral and blood-borne infections in blood donors of Tehran. *Sci J Iranian Blood Transfus Organ* 2006; 2: 353-364.
250. Khedmat H, Alavian SM, Miri SM, et al. Trends in seroprevalence of hepatitis B, hepatitis C, HIV, and syphilis infections in Iranian blood donors from 2003 to 2005. *Hepatitis Monthly* 2009; 9: 24-28.

251. Khedmat H, Fallahian F, Abolghasemi H, et al. Seroepidemiologic study of hepatitis B virus, hepatitis C virus, human immunodeficiency virus and syphilis infections in Iranian blood donors. *Pakistan J Biol Sci PJBS* 2007; 10: 4461-4466.
252. Pourfathollah AA. Changes in frequency of HBV, HCV, HIV and syphilis infections among blood donors in Tehran province 2005-2011. *Arch Iranian Med* 2014; 17: 613-620.
253. Keshvari M, Sharafi H, Alavian SM, Mehrabadi H, Zolfaghari S. Prevalence and trends of transfusion-transmitted infections among blood donors in Tehran, Iran from 2008 to 2013. *Transfus Apher Sci* 2015; 53: 38-47.
254. Saber HR, Tabatabaee SM, Abasian A, et al. Incidence and residual risk of HIV, HBV and HCV infections among blood donors in Tehran. *Indian J Hematol Blood Transfus* 2017; 33: 412-416.
255. Shahshahani HJ, Vaziri M, Mansouri F. Seven years trends in prevalence of transfusion-transmissible viral infections in Yazd blood transfusion organization. *Iranian J Pediatr Hematol Oncol* 2013; 3: 119-124.
256. Maghsoodlu M, Salehifar P, Rahimzadeh P, et al. Prevalence and trends of transfusion-transmissible infections and study of confidential unit exclusion among blood donors in Kurdistan province of Iran. *Int J Med Lab* 2018; 5: 58-65.
257. Sajjadi SM, Pourfathollah AA, Mohammadi S, Nouri B, Hassanzadeh R, Rad F. The prevalence and trends of hepatitis B, hepatitis C, and HIV among voluntary blood donors in Kohgiluyeh and Boyer-Ahmad Transfusion Center, Southwestern Iran. *Iranian J Public Health* 2018; 47: 944-951.
258. Niazkari HR, Dorgalaleh A, Rad F. First-time blood donors are double edged swords for blood transfusion centers: a retrospective study in Southwest Iran. *Turk J Haematol* 2020; 37: 30-35.
259. Kafi-abad SA, Rezvan H, Abolghasemi H, Talebian A. Prevalence and trends of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus among blood donors in Iran, 2004 through 2007. *Transfusion* 2009; 49: 2214-2220.
260. Soodejani MT, Haghdoost AA, Sedaghat A, Baneshi MR, Zolala F. The trends of viral hepatitis B and C and HIV infections in donated bloods in Iran between 2003 and 2017. *J Blood Med* 2019; 10: 435-441.
261. Habibzadeh S, Davarnia B, Bagherzadeh S, Hamid G. Epidemiological evaluation of transfusion transmitted diseases in Ardabil in Tasoua and Ashoura 1381 (2003). *Sci J Iran Blood Transfus Organ* 2005; 1: 55-60.
262. Ghafouri M, Ameli M. Comparing prevalence of transfusion transmitted viral infections in various population groups of South Khorasan. *Sci J Iran Blood Transfus Organ* 2011; 7: 242-248.
263. Yazhan S, Sohrabi E, Jamili P, Saffari S, Mojaddadi MS. Frequency of HBV, HCV and HIV infections among Sabzevar blood donors based on demographic characteristics during 2009-2013. *Sci J Iran Blood Transfus Organ* 2016; 13: 197-206.
264. Sorouri Zanjani R, Mazloomzadeh S, Koocheki A, Noori M. Prevalence of hepatitis B, C and HIV infection in blood donors in Zanjan, 2005-2006. *Prev Care Nurs Midwifery J* 2013; 3: 56-63.
265. Bozorgi SH, Ramezani H, Nooranipour M, et al. Risk factors of viral hepatitis: yet to explore. *Transfus Apher Sci* 2012; 47: 145-149.
266. Mahdavian F, Saremi S, Maghsoodlu M, Pourfathollah A. Prevalence of blood transmitted viral infections in regular and non-regular donors of Arak Blood Center. *Sci J Iran Blood Transfus Organ* 2006; 2: 343-351.